 |
市場調查報告書
商品編碼
1638756
2024 - 2032 年臨床參考實驗室市場機會、成長動力、產業趨勢分析與預測Clinical Reference Laboratory Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
||||||
2023 年，全球臨床參考實驗室市場估值為 456 億美元，預計 2024 年至 2032 年複合年成長率為 6.2%。醫療保健不可或缺的一部分。這些設施為醫療保健提供者、醫院和其他實驗室提供服務，提供廣泛的檢測服務，從常規篩檢到複雜的遺傳和特定疾病的診斷。
慢性病和傳染病的盛行率不斷上升，極大地推動了市場的成長，從而刺激了對診斷測試的需求，特別是在管理慢性病方面。全球疾病負擔不斷上升凸顯了臨床參考實驗室的重要作用，其中先進的血液檢測、基因篩檢和生物標記分析等服務對於早期檢測、有效的疾病管理和長期健康監測至關重要。
按服務類型細分，市場包括醫院實驗室、獨立實驗室和診所實驗室。 2023 年，以醫院為基礎的細分市場處於領先地位，估值約 223 億美元。這些醫院實驗室提供廣泛的測試（從基礎血液檢查到複雜的分子診斷），使醫療保健提供者能夠利用集中中心進行全面診斷，最終提高病患照護效率。
| 市場範圍 | |
|---|---|
| 開始年份 | 2023年 |
| 預測年份 | 2024-2032 |
| 起始值 | 456 億美元 |
| 預測值 | 780 億美元 |
| 複合年成長率 | 6.2% |
從應用來看，市場分為臨床試驗和檢驗醫學，到2023年，檢驗醫學將佔據超過67.6%的市場佔有率。醫療保健領域發揮基礎作用。此類臨床參考實驗室進行深入的生化分析，以評估器官功能、檢測代謝紊亂和監測慢性病，從而支持全面的患者健康管理。
光是美國臨床參考實驗室市場就在 2023 年達到 169 億美元，其基礎是糖尿病、癌症和自體免疫疾病等慢性病的高盛行率。這些實驗室是美國醫療保健的核心，提供先進的生化和分子診斷，以提高患者護理品質和健康結果。由臨床實驗室改進修正案 (CLIA) 和 FDA 等實體領導的美國監管環境對實驗室操作執行嚴格的標準，確保這個快速發展的行業的測試精度和患者安全。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 慢性病和傳染病的發生率上升
- 生物參考實驗室數量不斷增加
- 診斷測試數量不斷增加
- 老年人口不斷增加
- 產業陷阱與挑戰
- 先進技術成本高
- 嚴格的監理政策
- 成長動力
- 成長潛力分析
- 監管環境
- 技術景觀
- 核心技術
- 鄰近技術
- 未來市場趨勢
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按服務類型，2021 - 2032 年
- 主要趨勢
- 以醫院為基礎
- 獨立式
- 以臨床為基礎
第 6 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 臨床試驗
- 檢驗醫學
第 7 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
第 8 章：公司簡介
- Al Borg Medical Laboratories
- Ampath Laboratories
- ARUP Laboratories
- Biolab
- Eurofins Scientific
- Laboratory Corporation of America Holdings
- Laboratoires Reunis
- Lifebrain Group
- Lancet Laboratories
- Mayo Clinic Laboratories
- Medsol Diagnostics
- Quest Diagnostics
- Sonic Healthcare
- Synlab Group
- Unilabs
The Global Clinical Reference Laboratory Market was valued at USD 45.6 billion in 2023 and is projected to grow at a 6.2% CAGR from 2024 to 2032. Clinical reference laboratories, specialized in performing advanced diagnostic tests on samples like blood, urine, and tissue, are integral to modern healthcare. These facilities cater to healthcare providers, hospitals, and other labs, offering a wide range of testing services, from routine screenings to complex genetic and disease-specific diagnostics.
The market's growth is significantly driven by the increasing prevalence of chronic and infectious diseases, fueling the demand for diagnostic testing, particularly in managing chronic conditions. Rising global disease burdens underscore the essential role of clinical reference labs, where services such as advanced blood tests, genetic screenings, and biomarker analyses are crucial for early detection, effective disease management, and long-term health monitoring.
Segmented by service type, the market includes hospital-based, standalone, and clinic-based laboratories. In 2023, the hospital-based segment led with a valuation of approximately USD 22.3 billion. These hospital-based labs offer an extensive range of tests-spanning from basic blood work to sophisticated molecular diagnostics-allowing healthcare providers to leverage a centralized hub for comprehensive diagnostics, ultimately enhancing patient care efficiency.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $45.6 Billion |
| Forecast Value | $78 Billion |
| CAGR | 6.2% |
For applications, the market is divided into clinical trials and laboratory medicine, with laboratory medicine claiming over 67.6% of the market share in 2023. This segment plays a foundational role in healthcare by supplying essential diagnostic information that helps disease prevention, diagnosis, and treatment. Clinical reference labs within this category conduct in-depth biochemical analyses to assess organ function, detect metabolic disorders, and monitor chronic conditions, thereby supporting holistic patient health management.
The U.S. clinical reference laboratory market alone reached USD 16.9 billion in 2023, underpinned by a high prevalence of chronic diseases such as diabetes, cancer, and autoimmune disorders. These laboratories are central to U.S. healthcare, providing advanced biochemical and molecular diagnostics that elevate patient care quality and health outcomes. The U.S. regulatory environment, led by entities like the Clinical Laboratory Improvement Amendments (CLIA) and the FDA, enforces rigorous standards for laboratory operations, ensuring testing precision and patient safety in this rapidly growing sector.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising incidence of chronic and infectious diseases
- 3.2.1.2 Growing number of bio reference laboratories
- 3.2.1.3 Increasing number of diagnostic testing
- 3.2.1.4 Rising geriatric population
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of advanced technologies
- 3.2.2.2 Presence of stringent regulatory policies
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Service Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Hospital-based
- 5.3 Standalone
- 5.4 Clinic-based
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Clinical trials
- 6.3 Laboratory medicine
Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Netherlands
- 7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
- 7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE
Chapter 8 Company Profiles
- 8.1 Al Borg Medical Laboratories
- 8.2 Ampath Laboratories
- 8.3 ARUP Laboratories
- 8.4 Biolab
- 8.5 Eurofins Scientific
- 8.6 Laboratory Corporation of America Holdings
- 8.7 Laboratoires Reunis
- 8.8 Lifebrain Group
- 8.9 Lancet Laboratories
- 8.10 Mayo Clinic Laboratories
- 8.11 Medsol Diagnostics
- 8.12 Quest Diagnostics
- 8.13 Sonic Healthcare
- 8.14 Synlab Group
- 8.15 Unilabs
